Oncogenic signaling of class I PI3K isoforms

The catalytic subunits of class I PI3Ks comprise four isoforms: p110α, p110β, p110δ and p110γ. Cancer-specific gain-of-function mutations in p110α have been identified in various malignancies. Cancer-specific mutations in the non-α isoforms of class I PI3K have not yet been identified, however overexpression of either wild-type p110β, p110γ or p110δ is sufficient to induce cellular transformation in chicken embryo fibroblasts. The mechanism whereby these non-α isoforms of class I mediate oncogenic signals is unknown. Here we show that potently transforming class I isoforms signal via Akt/mTOR, inhibit GSK3β and cause degradation of FoxO1. A functional Erk pathway is required for p110γ and p110β transformation but not for transformation by p110δ or the H1047R mutant of p110α. Transformation and signaling by p110γ and p110β are sensitive to loss of interaction with Ras, which acts as a membrane anchor. Mutations in the C2 domain of p110δ reduce transformation, most likely by interfering with membrane association. Several small molecule inhibitors potently and specifically inhibit the oncogenic signaling and transformation of each of the class I PI3K, and, when used in combination with MEK inhibitors, can additively reduce the transformation induced by p110β and p110γ.

[1]  William A Weiss,et al.  Isoform Specific Inhibitors of PI3 Kinase in Glioma , 2006, Cell cycle.

[2]  P. Vogt,et al.  The akt kinase: molecular determinants of oncogenicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[4]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[5]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Südhof,et al.  C2-domains, Structure and Function of a Universal Ca2+-binding Domain* , 1998, The Journal of Biological Chemistry.

[7]  Phillip T. Hawkins,et al.  Gβγs and the Ras binding domain of p110γ are both important regulators of PI3Kγ signalling in neutrophils , 2006, Nature Cell Biology.

[8]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[9]  Hervé Guillou,et al.  Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. , 2006, Nature cell biology.

[10]  T. Ishida,et al.  Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation , 2004, Leukemia.

[11]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[12]  R. Medema,et al.  Myc‐induced proliferation and transformation require Akt‐mediated phosphorylation of FoxO proteins , 2004, The EMBO journal.

[13]  K. Okkenhaug,et al.  Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. , 2003, The Journal of biological chemistry.

[14]  A. Khwaja,et al.  PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.

[15]  D. F. Barber,et al.  PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus , 2005, Nature Medicine.

[16]  P. Finan,et al.  Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. , 2004, Nature.

[17]  Emilio Hirsch,et al.  Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis , 2005, Nature Medicine.

[18]  A. Robertson,et al.  PI 3-kinase p110beta: a new target for antithrombotic therapy. , 2005, Nature medicine.

[19]  P. Vogt,et al.  A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Loda,et al.  The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Nishizawa,et al.  New procedure for DNA transfection with polycation and dimethyl sulfoxide , 1984, Molecular and cellular biology.

[22]  T. Skorski,et al.  Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571 , 2002, Oncogene.

[23]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[24]  C. Billottet,et al.  A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. , 2006, Oncogene.

[25]  J. McCubrey,et al.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention , 2003, Leukemia.

[26]  P. Finan,et al.  Therapeutic potential of phosphoinositide 3-kinase inhibitors. , 2003, Chemistry & biology.

[27]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.

[28]  K. Okkenhaug,et al.  Class I Phosphoinositide 3-Kinase p110β Is Required for Apoptotic Cell and Fcγ Receptor-mediated Phagocytosis by Macrophages* , 2003, Journal of Biological Chemistry.

[29]  P. Vogt,et al.  The Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity* , 2000, The Journal of Biological Chemistry.

[30]  A. Bilancio,et al.  Signalling by PI3K isoforms: insights from gene-targeted mice. , 2005, Trends in biochemical sciences.

[31]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[32]  G. Bollag,et al.  Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.

[33]  D. Staunton,et al.  Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement , 2003, The Journal of Immunology.

[34]  S. Leevers,et al.  Input from Ras is required for maximal PI(3)K signalling in Drosophila , 2006, Nature Cell Biology.

[35]  L. Pirola,et al.  Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK. , 1998, Science.

[36]  P. Finan,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. , 2003, Current opinion in pharmacology.

[37]  Michael G. Kharas,et al.  Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. , 2004, Blood.

[38]  D. Staunton,et al.  Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. , 2003, Journal of immunology.

[39]  P. Vogt,et al.  PI 3-Kinases: Hidden Potentials Revealed , 2006, Cell cycle.

[40]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[41]  A. Robertson,et al.  PI 3-kinase p110β: a new target for antithrombotic therapy , 2005, Nature Medicine.

[42]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Condeelis,et al.  Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells. , 2004, Cell motility and the cytoskeleton.

[44]  Philip R. Cohen,et al.  Further evidence that the inhibition of glycogen synthase kinase‐3β by IGF‐1 is mediated by PDK1/PKB‐induced phosphorylation of Ser‐9 and not by dephosphorylation of Tyr‐216 , 1997, FEBS letters.

[45]  T. Cotter,et al.  BCR-ABL Regulates Phosphatidylinositol 3-Kinase-p110γ Transcription and Activation and Is Required for Proliferation and Drug Resistance* , 2006, Journal of Biological Chemistry.

[46]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[47]  K. Okkenhaug,et al.  Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.

[48]  G. Zon,et al.  C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. , 1995, Cancer research.

[49]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[50]  J. Cheong,et al.  Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable , 2003, Leukemia.

[51]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[52]  M. Crackower,et al.  A Specific Role of Phosphatidylinositol 3–Kinase γ , 2001, The Journal of cell biology.

[53]  W L Stanford,et al.  Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. , 2000, Science.

[54]  J. Falke,et al.  The C2 domain calcium‐binding motif: Structural and functional diversity , 1996, Protein science : a publication of the Protein Society.

[55]  P. Hawkins,et al.  Signalling through Class I PI3Ks in mammalian cells. , 2006, Biochemical Society transactions.

[56]  T. Hunter,et al.  Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  C. Chang,et al.  Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. , 1990, Genes & development.

[58]  G. Mills,et al.  Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. , 2005, Cancer research.

[59]  C. Heldin,et al.  The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. , 2000, Journal of cell science.

[60]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[61]  P. Finan,et al.  Essential role for the p110δ phosphoinositide 3-kinase in the allergic response , 2004, Nature.

[62]  E. Solary,et al.  Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .

[63]  C. Zheng,et al.  Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. , 1994, The EMBO journal.

[64]  J. Condeelis,et al.  Over-expression of the p110β but not p110α isoform of PI 3-kinase inhibits motility in breast cancer cells , 2004 .

[65]  R. Nussbaum,et al.  Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.

[66]  M. Waterfield,et al.  Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages , 1999, Nature Cell Biology.

[67]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[68]  H. Wu,et al.  PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. , 2006, Oncogene.

[69]  J. McCubrey,et al.  Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia , 2003, Leukemia.

[70]  J. McCubrey,et al.  Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. , 2001, Cancer detection and prevention.

[71]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[72]  Yuval Inbar,et al.  Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.

[73]  T. Meyer,et al.  PI(3,4,5)P3 and PI(4,5)P2 Lipids Target Proteins with Polybasic Clusters to the Plasma Membrane , 2006, Science.

[74]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[75]  H. Wu,et al.  PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer , 2006, Oncogene.

[76]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[77]  E. Solary,et al.  Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.

[78]  J. Olefsky,et al.  A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. , 2000, Molecular endocrinology.

[79]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Hao Jiang,et al.  Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[81]  A M Martelli,et al.  Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia , 2006, Leukemia.

[82]  G. Panayotou,et al.  Phosphoinositide 3-kinases: a conserved family of signal transducers. , 1997, Trends in biochemical sciences.

[83]  R. Nussbaum,et al.  Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase , 2002, Mammalian Genome.

[84]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[85]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[86]  A. Newton,et al.  Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. , 1998, Biochimica et biophysica acta.